Cytomegalovirus (CMV) infection remains a serious problem in lung transplant recipients.
Development of potent oral antiviral agents, molecular techniques for the detection of
infection and its response to therapy and the emergence of isolates with antiviral resistance
have had significant impacts on the approach to CMV in these patients. This article
discusses the following issues as part of a comprehensive CMV management strategy in
lung transplant recipients:(1) Prevention strategies in the era of potent oral antiviral …